This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Eli Lilly & Company

Drug Names(s): IMC-1C11

Description: IMC-1C11 is a monoclonal antibody that targets an epidermal growth factor receptor (EGFR) family member called KDR (VEGFR2). In so doing, it inhibits vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, thus inhibiting angiogenesis (new blood supply) by blocking the development of capillaries from pre-existing blood vessels to tumors.

Deal Structure: In November 2008 Eli Lilly completed the acquisition of ImClone Systems.

IMC-1C11 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug